Domestic
Equity active
Equity active
RISE Bio TOP10 Active (0000Z0)
Update : 2026.09.21
NAV
8,157KRW
-0.1하락 (-%)
Market Price per share (KRW)
8,130KRW
-170하락 (-2.05%)
※ t-1 last price
trading volume
125,350shares
AUM
KRW 47.7billion
KEY POINT
An Active ETF Investing in 10 Key Domestic Pharmaceutical and Bio Companies Expanding Globally
-
KEY POINT
An Active ETF Designed to Quickly Respond to Technological Advancements, Regulatory Changes, Drug Approvals, and Individual Company Events.
-
| ETF Name (code) | Benchmark Index | Inception date | Creation Unit | AUM (KRW) |
|---|---|---|---|---|
| KB RISE Bio TOP10 Active ETF
(0000Z0) |
KRX Bio TOP 10 Index | 2024.12.24 | 50,000 | 47,720,180,379 |
| Trustee | Market Price per share (KRW) | NAV | Trading Volume (shares) | |
| 한국씨티은행 |
8,130
※ t-1 last price |
8,157 | 125,350 |
| Total Expense Ratio | Distribution Frequency |
|---|---|
| Year 0.5% (Designated participating company : 0.001%, Collective investment : 0.459%, trust : 0.02%, General affairs : 0.02%) | End date of the accounting period (If the end of the accounting period is not a business day, the business day immediately preceding it) |
| Authorized Participants | Liquidity Providers |
| Kiwoom Securities, NH Investment & Securities, KB Securities | Kiwoom Securities, NH Investment & Securities, KB Securities |
| ETF Name(Code) | Benchmark Index |
|---|---|
|
KB RISE Bio TOP10 Active ETF (0000Z0) |
KRX Bio TOP 10 Index |
| Inception date | Creation Unit |
| 2024.12.24 | 50,000 |
| AUM(0.1 billion) (KRW) | Trustee |
| 47,720,180,379 | 한국씨티은행 |
| Market Price per share (KRW) | iNAV per share (KRW) |
|
8,130
※ t-1 last price |
8,157 |
| Trading Volume (shares) | |
| 125,350 |
| Total Expense Ratio |
|---|
| Year 0.5% (Designated participating company : 0.001%, Collective investment : 0.459%, trust : 0.02%, General affairs : 0.02%) |
Distribution Frequency
|
| End date of the accounting period (If the end of the accounting period is not a business day, the business day immediately preceding it) |
| Authorized Participants |
| Kiwoom Securities, NH Investment & Securities, KB Securities |
| Liquidity Providers |
| Kiwoom Securities, NH Investment & Securities, KB Securities |
Index Introduction
The 'KRX Bio TOP 10 Index', calculated and announced by the Korea Exchange (KRX), consisting of 10 representative companies within the Bio industry sector listed on the KOSPI and KOSDAQ markets.
View detailed index informationTOP 10 Holdings
Update : 2026-09-21
| Rank | Name | Weight (%) |
|---|---|---|
| 1 | OliX | 9.33 |
| 2 | Alteogen | 8.83 |
| 3 | Celltrion | 8.49 |
| 4 | HanmiPharm | 8.26 |
| 5 | LCB | 7.22 |
| 6 | ABL Bio | 6.08 |
| 7 | ST Pharm | 5.30 |
| 8 | HANALL BIOPHARMA | 5.00 |
| 9 | PharmaResearch | 4.90 |
| 10 | OCT Inc. | 4.53 |
proportion by sectors
*The proportion of investment stocks
Update : 2026.09.21
| Rank | Name | Weight (%) |
|---|---|---|
| 1 | Healthcare | 100.00 |
Dividend payment data
· Payable date of dividend payment 3 years.| Rule of Dividend payment | Payable date of dividend payment | dividend per share (KRW) |
|---|---|---|
| 2026-07-31 | 2026-08-04 | 2 |
| 2025-12-30 | 2026-01-05 | 2 |
- Investment notice
- - The information provided on this website is based on reliable sources, but its accuracy and completeness are not guaranteed.
- - Financial investment products are not protected by the Korea Deposit Insurance Corporation in accordance with the Depositor Protection Act, and a loss of investment principal may occur, which belongs to the investor.
- - Past performance does not guarantee future profits.
- - In the case of a collective investment scheme that invests in foreign securities, asset values may be lost due to risks caused by market, political, and economic conditions in the target country.
- - Derivatives may lose all or a significant portion of the investment principal in a short period of time due to high price volatility, and there is a risk that the counterparty may not be able to fulfill the terms of the contract when investing in over-the-counter derivatives.
- - Before investing, be sure to read the investment prospectus and contract recommendation document regarding the investment subject, redemption method, and fee.